PhotoPoint™ photodynamic therapy with local drug delivery eliminates vessel wall cells in arteriovenous graft models

Julie M. Burgher, Jennifer M. Barton, Michael M. Farooq, Jeff Vasek, Robert W. Scott, Julie A. Freischlag, Robert I. Grove

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To demonstrate the feasibility of PhotoPoint photodynamic therapy (PDT) with local drug delivery, optimize dosimetry in a rabbit jugular vein model, and investigate its ability to deplete potential neointimal precursor cells in the vessel wall in a canine arteriovenous graft (AVG) model. Methods and materials: Photosensitizer MV2101 was administered locally in rabbit veins, incubated for 0-40 min and activated with external laser light. In canine veins, MV2101 was incubated for 30 min and activated by light. Tissues were excised at acute and chronic timepoints. Results: PhotoPoint PDT reduced cell populations in both models with maximum depletions occurring at 20 min (≥100 J/cm2) in rabbit veins (>90% depletion) and 30 min (200 J/cm 2) in canine veins (>85% depletion). Chronic veins revealed no evidence of PhotoPoint PDT-related abnormalities. Conclusions: PhotoPoint PDT with local MV2101 dramatically depleted potential neointimal precursor cells in the vessel wall. This suggests local drug delivery is feasible and that PhotoPoint PDT may be an efficacious treatment that could prolong AVG patency in the clinic.

Original languageEnglish (US)
Pages (from-to)163-168
Number of pages6
JournalCardiovascular Radiation Medicine
Volume3
Issue number3-4
DOIs
StatePublished - Jul 2002

Fingerprint

Photochemotherapy
Cell Wall
Veins
Transplants
Canidae
Pharmaceutical Preparations
Rabbits
Light
Photosensitizing Agents
Jugular Veins
Lasers
Population

Keywords

  • Arteriovenous access graft
  • AVG
  • Canine
  • Intimal hyperplasia
  • Local drug administration
  • PDT
  • Photodynamic therapy
  • PhotoPoint
  • Rabbit

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Burgher, J. M., Barton, J. M., Farooq, M. M., Vasek, J., Scott, R. W., Freischlag, J. A., & Grove, R. I. (2002). PhotoPoint™ photodynamic therapy with local drug delivery eliminates vessel wall cells in arteriovenous graft models. Cardiovascular Radiation Medicine, 3(3-4), 163-168. https://doi.org/10.1016/S1522-1865(03)00080-5

PhotoPoint™ photodynamic therapy with local drug delivery eliminates vessel wall cells in arteriovenous graft models. / Burgher, Julie M.; Barton, Jennifer M.; Farooq, Michael M.; Vasek, Jeff; Scott, Robert W.; Freischlag, Julie A.; Grove, Robert I.

In: Cardiovascular Radiation Medicine, Vol. 3, No. 3-4, 07.2002, p. 163-168.

Research output: Contribution to journalArticle

Burgher, Julie M. ; Barton, Jennifer M. ; Farooq, Michael M. ; Vasek, Jeff ; Scott, Robert W. ; Freischlag, Julie A. ; Grove, Robert I. / PhotoPoint™ photodynamic therapy with local drug delivery eliminates vessel wall cells in arteriovenous graft models. In: Cardiovascular Radiation Medicine. 2002 ; Vol. 3, No. 3-4. pp. 163-168.
@article{8947ce56645d47b1b668cbad0055ca36,
title = "PhotoPoint™ photodynamic therapy with local drug delivery eliminates vessel wall cells in arteriovenous graft models",
abstract = "Purpose: To demonstrate the feasibility of PhotoPoint photodynamic therapy (PDT) with local drug delivery, optimize dosimetry in a rabbit jugular vein model, and investigate its ability to deplete potential neointimal precursor cells in the vessel wall in a canine arteriovenous graft (AVG) model. Methods and materials: Photosensitizer MV2101 was administered locally in rabbit veins, incubated for 0-40 min and activated with external laser light. In canine veins, MV2101 was incubated for 30 min and activated by light. Tissues were excised at acute and chronic timepoints. Results: PhotoPoint PDT reduced cell populations in both models with maximum depletions occurring at 20 min (≥100 J/cm2) in rabbit veins (>90{\%} depletion) and 30 min (200 J/cm 2) in canine veins (>85{\%} depletion). Chronic veins revealed no evidence of PhotoPoint PDT-related abnormalities. Conclusions: PhotoPoint PDT with local MV2101 dramatically depleted potential neointimal precursor cells in the vessel wall. This suggests local drug delivery is feasible and that PhotoPoint PDT may be an efficacious treatment that could prolong AVG patency in the clinic.",
keywords = "Arteriovenous access graft, AVG, Canine, Intimal hyperplasia, Local drug administration, PDT, Photodynamic therapy, PhotoPoint, Rabbit",
author = "Burgher, {Julie M.} and Barton, {Jennifer M.} and Farooq, {Michael M.} and Jeff Vasek and Scott, {Robert W.} and Freischlag, {Julie A.} and Grove, {Robert I.}",
year = "2002",
month = "7",
doi = "10.1016/S1522-1865(03)00080-5",
language = "English (US)",
volume = "3",
pages = "163--168",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier Inc.",
number = "3-4",

}

TY - JOUR

T1 - PhotoPoint™ photodynamic therapy with local drug delivery eliminates vessel wall cells in arteriovenous graft models

AU - Burgher, Julie M.

AU - Barton, Jennifer M.

AU - Farooq, Michael M.

AU - Vasek, Jeff

AU - Scott, Robert W.

AU - Freischlag, Julie A.

AU - Grove, Robert I.

PY - 2002/7

Y1 - 2002/7

N2 - Purpose: To demonstrate the feasibility of PhotoPoint photodynamic therapy (PDT) with local drug delivery, optimize dosimetry in a rabbit jugular vein model, and investigate its ability to deplete potential neointimal precursor cells in the vessel wall in a canine arteriovenous graft (AVG) model. Methods and materials: Photosensitizer MV2101 was administered locally in rabbit veins, incubated for 0-40 min and activated with external laser light. In canine veins, MV2101 was incubated for 30 min and activated by light. Tissues were excised at acute and chronic timepoints. Results: PhotoPoint PDT reduced cell populations in both models with maximum depletions occurring at 20 min (≥100 J/cm2) in rabbit veins (>90% depletion) and 30 min (200 J/cm 2) in canine veins (>85% depletion). Chronic veins revealed no evidence of PhotoPoint PDT-related abnormalities. Conclusions: PhotoPoint PDT with local MV2101 dramatically depleted potential neointimal precursor cells in the vessel wall. This suggests local drug delivery is feasible and that PhotoPoint PDT may be an efficacious treatment that could prolong AVG patency in the clinic.

AB - Purpose: To demonstrate the feasibility of PhotoPoint photodynamic therapy (PDT) with local drug delivery, optimize dosimetry in a rabbit jugular vein model, and investigate its ability to deplete potential neointimal precursor cells in the vessel wall in a canine arteriovenous graft (AVG) model. Methods and materials: Photosensitizer MV2101 was administered locally in rabbit veins, incubated for 0-40 min and activated with external laser light. In canine veins, MV2101 was incubated for 30 min and activated by light. Tissues were excised at acute and chronic timepoints. Results: PhotoPoint PDT reduced cell populations in both models with maximum depletions occurring at 20 min (≥100 J/cm2) in rabbit veins (>90% depletion) and 30 min (200 J/cm 2) in canine veins (>85% depletion). Chronic veins revealed no evidence of PhotoPoint PDT-related abnormalities. Conclusions: PhotoPoint PDT with local MV2101 dramatically depleted potential neointimal precursor cells in the vessel wall. This suggests local drug delivery is feasible and that PhotoPoint PDT may be an efficacious treatment that could prolong AVG patency in the clinic.

KW - Arteriovenous access graft

KW - AVG

KW - Canine

KW - Intimal hyperplasia

KW - Local drug administration

KW - PDT

KW - Photodynamic therapy

KW - PhotoPoint

KW - Rabbit

UR - http://www.scopus.com/inward/record.url?scp=0142227750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142227750&partnerID=8YFLogxK

U2 - 10.1016/S1522-1865(03)00080-5

DO - 10.1016/S1522-1865(03)00080-5

M3 - Article

VL - 3

SP - 163

EP - 168

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

IS - 3-4

ER -